Acute ischemic stroke caused by cervical artery dissection poses a complex therapeutic dilemma for modern neurointerventional teams. Clinicians frequently debate whether administering IV thrombolysis before thrombectomy offers tangible clinical benefit or introduces avoidable hemorrhagic dangers. Cervical dissections often trigger intraluminal thrombus formation alongside structural vessel wall instability. Consequently, stroke specialists must carefully weigh the risk of local intramural hematoma expansion against the urgent imperative of intracranial recanalization. Therefore, understanding optimal reperfusion strategies remains critical for optimizing long-term neurological recovery in acute ischemic stroke patients.

Efficacy of IV Thrombolysis Before Thrombectomy in Carotid Dissection

The CONCORDIA and ETIS multicenter registry collaborative study systematically evaluated the clinical utility of bridging fibrinolysis in this setting. Researchers examined 1,091 consecutive adult patients with anterior-circulation large-vessel occlusion secondary to carotid artery dissection. Among this international cohort, 571 individuals received intravenous thrombolytic infusion prior to endovascular therapy, whereas 520 patients proceeded straight to mechanical thrombectomy alone. The authors utilized rigorous inverse probability of treatment weighting to adjust for underlying baseline imbalances between treatment groups.

Consequently, the investigators observed that administering bridging thrombolysis yielded substantial functional improvements. Patients receiving pre-procedural thrombolytics demonstrated a significantly higher probability of achieving functional independence at three months, defined as a modified Rankin Scale score of 0 to 2. Specifically, the adjusted risk ratio reached 1.16, confirming an independent positive association with favorable functional recovery. Moreover, this functional advantage persisted across multiple sensitivity models, confirming the reliability of the primary analytical findings. In addition, younger patients and those presenting with severe baseline neurological deficits experienced pronounced functional recovery. Thus, the clinical registry data strongly indicate that initiating medical fibrinolysis before mechanical intervention enhances overall neurological recovery without causing harm.

Reperfusion Dynamics and Angiographic Success

Achieving complete and timely recanalization represents the primary cornerstone of modern neurovascular stroke rescue. In this registry cohort, pre-interventional thrombolytic therapy substantially increased the odds of establishing successful vessel patency. The investigators defined successful reperfusion as an expanded Thrombolysis in Cerebral Infarction score of 2b or higher. Notably, patients in the combined therapy arm attained significantly higher rates of successful angiographic reperfusion compared to those undergoing direct mechanical intervention.

Furthermore, the adjusted risk ratio for successful reperfusion was 1.34, representing an absolute enhancement in procedural technical efficacy. Thrombolytic agents often soften acute intraluminal clots before catheter manipulation commences. Consequently, interventionalists can extract softer, partially dissolved thrombi with fewer stent-retriever passes or aspiration attempts. In addition, chemical lysis targets microvascular distal emboli that mechanical tools cannot physically reach. Therefore, systemic fibrinolytic agents protect downstream microvascular beds during mechanical recanalization maneuvers. Furthermore, shorter procedural durations reduce overall fluoroscopy exposure and procedural anesthesia complications. As a direct result, bridging therapy fosters both macrovascular recanalization and microvascular tissue perfusion, ultimately improving long-term tissue salvage.

Safety Profile and Hemorrhagic Transformation Risks

Safety considerations often make clinicians hesitate to administer intravenous fibrinolytics to dissection patients. Many practitioners fear that systemic thrombolysis might exacerbate intramural hematomas, precipitate pseudoaneurysm formation, or cause vessel perforation during subsequent endovascular manipulation. In addition, the risk of symptomatic intracranial hemorrhage remains a perpetual concern in large-territory cerebral ischemia. However, the comprehensive data from this large international study provide reassuring evidence regarding procedural safety.

Importantly, the incidence of symptomatic intracranial hemorrhage did not differ significantly between patients receiving bridging therapy and those undergoing direct thrombectomy. Systemic fibrinolysis did not provoke intramural expansion or arterial rupture within the dissected carotid segment. Similarly, three-month all-cause mortality rates remained comparable between the two treatment arms. These safety outcomes highlight that fibrinolytic therapy does not compromise arterial structural integrity when clinicians adhere to standard clinical protocols. Furthermore, parenchymal hematoma rates remained virtually identical across both cohorts. Therefore, the theoretical risk of catastrophic vascular extension should not prevent eligible stroke patients from receiving time-critical pharmacological thrombolysis.

Mechanistic Insights Into Carotid Dissection Thrombi

Understanding the unique pathophysiology of internal carotid artery dissection explains why pharmacotherapy synergizes effectively with endovascular devices. A mechanical tear within the vessel tunica intima exposes subendothelial collagen and tissue factor directly to circulating platelets. Consequently, this highly thrombogenic milieu generates fresh, fibrin-rich intraluminal thrombi that frequently propagate downstream into intracranial large vessels.

Because these newly formed clots possess high fibrin content, they remain highly susceptible to enzymatic dissolution by recombinant tissue plasminogen activators. Furthermore, intravenous alteplase or tenecteplase can dissolve microthrombi that break away during mechanical stent-retriever deployment. Without concurrent chemical lysis, these migrating fragments frequently occlude distal cortical branches, causing secondary ischemic damage. In addition, early medical thrombolysis helps maintain collateral leptomeningeal circulation while the patient travels to the neurointerventional angiosuite. Therefore, bridging medical therapy actively stabilizes the ischemic penumbra throughout the pre-interventional transit interval. Moreover, chemical thrombus digestion decreases clot adhesion to the inflamed arterial endothelium, facilitating smoother endovascular extraction.

Optimizing Acute Stroke Pathways and Protocols

These registry findings provide clear actionable guidance for emergency physicians, neurologists, and neurointerventional teams handling acute stroke admissions. First, emergency protocols should strictly avoid delaying intravenous thrombolytic infusion while arranging endovascular suite logistics. Because every minute of ischemic delay destroys millions of cortical neurons, teams must execute both pharmacological and mechanical workflows in parallel.

Moreover, clinicians must ensure prompt diagnostic neuroimaging to differentiate extracranial dissection from atherosclerotic disease. Non-invasive computed tomography angiography enables rapid vessel visualization without delaying intravenous treatment initiation. Once teams identify large-vessel occlusion, administering intravenous thrombolysis immediately before catheterization establishes the optimal foundation for comprehensive reperfusion. Furthermore, comprehensive stroke centers should update local management guidelines to reflect these real-world findings. In addition, telestroke networks can leverage these findings to initiate thrombolysis at primary care centers before inter-facility transit. By removing unwarranted hesitation around thrombolytic administration in carotid dissection, hospital systems can maximize functional independence and optimize clinical outcomes for stroke patients worldwide.

Frequently Asked Questions

Does pre-treatment with IV thrombolysis increase intracranial hemorrhage in carotid dissection?

The large multicenter study demonstrated no significant increase in symptomatic intracranial hemorrhage among patients receiving intravenous thrombolysis before mechanical thrombectomy. Rates of hemorrhagic transformation and three-month mortality remained equivalent between groups, confirming that bridging thrombolysis provides substantial functional benefits without compromising safety in carotid dissection patients.

Why does bridging thrombolysis improve reperfusion rates during endovascular thrombectomy?

Intravenous thrombolytic agents soften acute fibrin-rich thrombi before mechanical intervention begins, allowing interventionalists to extract clots more easily with fewer device passes. Additionally, thrombolytics dissolve downstream microvascular emboli that catheters cannot physically reach, thereby improving distal capillary bed perfusion and accelerating overall angiographic recanalization.

Should clinicians delay mechanical thrombectomy to observe response to intravenous thrombolysis?

Clinicians should never delay mechanical thrombectomy to observe patient response to intravenous thrombolytic infusion. Instead, acute stroke care teams must execute parallel workflows, initiating systemic thrombolysis immediately while simultaneously preparing the neurointerventional catheterization laboratory. Rapid mechanical recanalization remains essential to halt irreversible brain infarction.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Hotz JF et al. IV Thrombolysis Before Thrombectomy in Carotid Artery Dissection-Related Large-Vessel Occlusion. Neurology. 2026 Jun 23. doi: 10.1212/WNL.0000000000218125. PMID: 42202237.
2. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731.
3. Turc G, Tsivgoulis G, Amlani S, et al. European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischemic Stroke. J Neurointerv Surg. 2023;15(7):e3.